On June 28, Gelonghui announced that Guangdong Zhongsheng Pharmaceutical, a wholly-owned subsidiary of Guangdong Southern Pharmaceutical Group Co., Ltd., received the Drug Registration Certificate of Ribavirin Tablets issued by the State Administration for Drug Regulation and Control.
Ribavirin tablets are a type of gastric mucosal protective agent that can protect the gastric mucosa and promote ulcer healing. Ribavirin tablets are listed as Class B drugs in the medical insurance catalog and are clinically used to improve acute exacerbation of gastric mucosal lesions (erosion, bleeding, congestion, and edema) in acute gastritis and chronic gastritis, as well as for the treatment of gastric ulcers.
According to the databases of Minet, the total sales of Ribavirin tablets in public hospitals and physical pharmacies in Chinese cities from 2021 to 2023 were RMB 728.54 million, RMB 750.44 million, and RMB 811.92 million, respectively.